Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

Baltimore, Maryland

CNS medication trials in Baltimore, MD

35 CNS medication studies are recruiting participants at sites in Baltimore as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Baltimore at a glance

  • 35 studies are recruiting at a site in Baltimore.
  • By phase: Early Phase 1 (1), Phase 1 (5), Phase 2 (6), Phase 3 (14), Phase 4 (6), No phase (3). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (20), university, hospital or other (13), government (2).
  • By research area: Depression (8), Multiple Sclerosis (8), Parkinson's Disease (8), Epilepsy (4), ADHD (3), Migraine (2), Bipolar Disorder (1), Schizophrenia (1).
  • Most recent update to one of these records: November 17, 2026.

Depression studies recruiting in Baltimore

Basic details from each study's public record (the 30 most recently updated of 35). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Pharmasite Research, Inc.
    Registry record
    NCT07412756 · updated
  2. Defining Neurobiological Links Between Substance Use and Mental Illness

    • No phase
    • Ages 18 to 60
    • All sexes
    Sponsor
    National Institute on Drug Abuse (NIDA)
    Study site
    National Institute on Drug Abuse
    Registry record
    NCT05538910 · updated
  3. A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Johns Hopkins University
    Registry record
    NCT07227454 · updated
  4. A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Pharmasite Research, Inc.
    Registry record
    NCT07573176 · updated
  5. A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Pharmasite Research, Inc.
    Registry record
    NCT07775300 · updated
  6. Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

    • Early Phase 1
    • Ages 18 to 85
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Center for Psychedelic and Consciousness Research
    Registry record
    NCT04123314 · updated
  7. Psilocybin in Chronic Low Back Pain and Depression

    • Phase 1
    • Ages 21 to 80
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins University School of Medicine
    Registry record
    NCT06355414 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Baltimore, MD on ClinicalTrials.gov.

Bipolar disorder studies recruiting in Baltimore

  1. The COSMYC Trial (COmbined Suppression of MYC)

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Study site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06922318 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in Baltimore, MD on ClinicalTrials.gov.

ADHD studies recruiting in Baltimore

  1. Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

    • Phase 4
    • From 48 months, up to 69 months
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Kennedy Krieger Institute
    Registry record
    NCT04781140 · updated
  2. Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

    • Phase 4
    • Ages 8 to 12
    • All sexes
    Sponsor
    Donald Gilbert, MD, MS, FAAN, FAAP
    Study site
    Kennedy Krieger Institute
    Registry record
    NCT04421248 · updated
  3. Medication Treatment of ADHD in Pediatric Epilepsy

    • Phase 4
    • Ages 6 to 17
    • All sexes
    Sponsor
    Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
    Study site
    Kennedy Krieger Institute
    Registry record
    NCT07594652 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Baltimore, MD on ClinicalTrials.gov.

Parkinson's disease studies recruiting in Baltimore

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    MedStar Franklin Square Medical Center ( Site 0031) · MedStar Good Samaritan Hospital ( Site 0079)
    Registry record
    NCT06841354 · updated
  2. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mercy Medical Center - Baltimore ( Site 0015)
    Registry record
    NCT06966700 · updated
  3. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  4. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    Johns Hopkins University
    Registry record
    NCT06996652 · updated
  5. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    • Phase 2
    • Ages 40 to 80
    • All sexes
    Sponsor
    Neuron23 Inc.
    Study site
    University of Maryland
    Registry record
    NCT06680830 · updated
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Greenebaum Comprehensive Cancer Center ( Site 0036)
    Registry record
    NCT06312176 · updated
  7. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT05142189 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Baltimore, MD on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in Baltimore

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT03816345 · updated
  2. Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    • Phase 2
    • Ages 18 to 60
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins University
    Registry record
    NCT07497399 · updated
  3. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Sanofi
    Study site
    Baltimore Veterans Affairs Medical Center- Site Number : 8400163
    Registry record
    NCT07325292 · updated
  4. The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

    • No phase
    • Ages 22 to 60
    • All sexes
    Sponsor
    SetPoint Medical Corporation
    Study site
    Johns Hopkins School of Medicine
    Registry record
    NCT06796504 · updated
  5. Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis

    • No phase
    • Ages 18 to 65
    • All sexes
    Sponsor
    University of Maryland, Baltimore
    Study site
    University of Maryland, Baltimore
    Registry record
    NCT06864936 · updated
  6. Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

    • Phase 2
    • Ages 18 to 60
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins University
    Registry record
    NCT06170970 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Baltimore, MD on ClinicalTrials.gov.

Epilepsy studies recruiting in Baltimore

  1. Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

    • Phase 3
    • Ages 4 to 55
    • All sexes
    Sponsor
    SK Life Science, Inc.
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT05219617 · updated
  2. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study sites
    MedStar Franklin Square Medical Center · University of Maryland Medical Center
    Registry record
    NCT05667142 · updated
  3. RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

    • Phase 2
    • Ages 18 to 70
    • All sexes
    Sponsor
    Supernus Pharmaceuticals, Inc.
    Study site
    Johns Hopkins University
    Registry record
    NCT06798896 · updated
  4. Ketogenic Diet for New-Onset Absence Epilepsy

    • Phase 3
    • Ages 3 to 12
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT04274179 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in Baltimore, MD on ClinicalTrials.gov.

Migraine studies recruiting in Baltimore

  1. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    University of Maryland School of Medicine
    Registry record
    NCT05164172 · updated
  2. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Pharmasite Research, Inc. /ID# 227908
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Baltimore, MD on ClinicalTrials.gov.

Ask about studies near Baltimore

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call